Publications by authors named "P Pregno"
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
February 2024
Article Synopsis
- - Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib have a risk of arterial occlusive events (AOEs), prompting recommendations for cardiovascular risk assessments before starting treatment.
- - A study of 455 CML patients showed that using the updated SCORE2/SCORE2-OP algorithm, which accounts for various cardiovascular risk factors, identified a greater percentage of patients at high risk compared to the older SCORE method.
- - Those classified as high to very high risk under SCORE2/SCORE2-OP experienced a significantly higher incidence of AOEs, emphasizing the algorithm's importance in guiding treatment decisions and enhancing patient care management.
Article Synopsis
- A study evaluated the safety and effectiveness of nilotinib as a first-line treatment for elderly patients (over 65) with chronic phase CML across 18 Italian centers, involving 60 patients with a median age of 72.
- At three months, all patients achieved a complete hematological response, with 71.6% showing an early molecular response and 78% achieving a complete cytogenetic response.
- While most patients tolerated the standard treatment dose well, some experienced side effects, and 10% had cardiovascular events, indicating that nilotinib can be effective but requires further long-term monitoring for potential dose adjustments to optimize safety.
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce.
View Article and Find Full Text PDFSystemic mastocytosis (SM) is a rare disease with a range of clinical presentations, and the vast majority of patients have a KIT D816V mutation that results in a gain of function. The multikinase/KIT inhibitor midostaurin inhibits the D816V mutant and has a well-established role in treating advanced SM. Even if considered the standard of therapy, some open questions remain on optimizing midostaurin management in daily practice.
View Article and Find Full Text PDFTreatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction is often used in real-life practice to reduce adverse events, although its impact on TFR is still a matter of debate. This study aimed to explore the attitude of Italian hematologists towards prescribing TKIs at reduced doses and its impact on TFR.
View Article and Find Full Text PDF